Studied in More Than 600 Women
In 4 clinical trials, BIKTARVY® was studied in more than 600 women living with HIV for varying periods of time who replaced or continued their current HIV-1 treatment.
In 2 of the trials, BIKTARVY was studied in over 150 women who replaced or continued their current treatment.*
-
Across these studies, BIKTARVY was evaluated in more than 1,100 adults (572 replaced treatment with BIKTARVY, and 568 continued their treatment*) over a 1-year period. At the end of 1 year, adults were given the option to either continue taking BIKTARVY or switch from their treatment to BIKTARVY. These groups were studied for an additional 1 or 2 years. Together, these trials included over 150 women on BIKTARVY.
In a third trial, BIKTARVY was studied exclusively in over 450 women who replaced or continued their current treatment.†
-
This study involved more than 450 adult women (234 replaced their current treatment with BIKTARVY and 236 continued their treatment) over a 1-year period. At the end of 1 year, adults were given the option to either continue taking BIKTARVY or switch from their treatment to BIKTARVY. These groups were studied for an additional year.
In a fourth trial, BIKTARVY was studied in over 30 pregnant women who replaced their current treatment.
-
This study involved more than 30 pregnant women who replaced their current treatment during their second or third trimester of pregnancy through 18 weeks after giving birth.
*The continued treatments were TRIUMEQ (abacavir, dolutegravir, lamivudine) or a combination of either EPZICOM® (abacavir, lamivudine) or TRUVADA® (emtricitabine, tenofovir disoproxil fumarate) + atazanavir or darunavir (with cobicistat or ritonavir).
†The other treatments were GENVOYA® (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide), STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), or REYATAZ® (atazanavir) + NORVIR® (ritonovir) + TRUVADA® (emtricitabine, tenofovir disoproxil fumarate).
The US department of Health and Human Services recommends that people living with HIV who are currently undetectable and able to tolerate potential side effects of BIKTARVY can continue taking BIKTARVY if they become pregnant.
Undetectable means the amount of virus in the blood is so low that it can’t be measured by a lab test.
-
Tell your healthcare provider if you are pregnant or plan to become pregnant while taking BIKTARVY.
-
If you are breastfeeding (nursing) or plan to breastfeed, talk to your healthcare provider about the risks of breastfeeding during treatment with BIKTARVY.
-
If you are pregnant and take supplements or antacids that contain aluminum, magnesium, iron, or calcium, talk to your healthcare provider about how to take BIKTARVY along with these supplements or antacids.
What is BIKTARVY®?
Expand
Collapse
BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in adults and children who weigh at least 55 pounds. It can either be used in people who have never taken HIV-1 medicines before, or people who are replacing their current HIV-1 medicines and whose healthcare provider determines they meet certain requirements.
BIKTARVY does not cure HIV-1 or AIDS. HIV-1 is the virus that causes AIDS.
What is BIKTARVY®?
BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in adults and children who weigh at least 55 pounds. It can either be used in people who have never taken HIV-1 medicines before, or people who are replacing their current HIV-1 medicines and whose healthcare provider determines they meet certain requirements.
BIKTARVY does not cure HIV-1 or AIDS. HIV-1 is the virus that causes AIDS.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about BIKTARVY®?
BIKTARVY may cause serious side effects:
- Worsening of hepatitis B (HBV) infection. Your healthcare provider will test you for HBV. If you have both HIV-1 and HBV and stop taking BIKTARVY, your HBV may suddenly get worse. Do not stop taking BIKTARVY without first talking to your healthcare provider, as they will need to monitor your health, and may give you HBV medicine.
Who should not take BIKTARVY?
Do not take BIKTARVY if you take:
- dofetilide
- rifampin
- any other medicines to treat HIV-1
What are the other possible side effects of BIKTARVY?
Serious side effects of BIKTARVY may also include:
- Changes in your immune system. Your immune system may get stronger and begin to fight infections that may have been hidden in your body. Tell your healthcare provider if you have any new symptoms after you start taking BIKTARVY.
- Kidney problems, including kidney failure. Your healthcare provider should do blood and urine tests to check your kidneys. If you develop new or worse kidney problems, they may tell you to stop taking BIKTARVY.
- Too much lactic acid in your blood (lactic acidosis), which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.
- Severe liver problems, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.
The most common side effects of BIKTARVY in clinical studies were diarrhea (6%), nausea (6%), and headache (5%). Tell your healthcare provider if you have any side effects that bother you or don’t go away.
What should I tell my healthcare provider before taking BIKTARVY?
- All your health problems. Be sure to tell your healthcare provider if you have or have had any kidney or liver problems, including hepatitis virus infection.
- All the medicines you take, including prescription and over-the-counter medicines, antacids, laxatives, vitamins, and herbal supplements. BIKTARVY and other medicines may affect each other. Keep a list of all your medicines and show it to your healthcare provider and pharmacist, and ask if it is safe to take BIKTARVY with all of your other medicines.
- If you are pregnant or plan to become pregnant. Tell your healthcare provider if you become pregnant while taking BIKTARVY.
- If you are breastfeeding (nursing) or plan to breastfeed. Talk to your healthcare provider about the risks of breastfeeding during treatment with BIKTARVY.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Important Facts about BIKTARVY, including important warnings.
What is BIKTARVY®?
BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in adults and children who weigh at least 55 pounds. It can either be used in people who have never taken HIV-1 medicines before, or people who are replacing their current HIV-1 medicines and whose healthcare provider determines they meet certain requirements.
BIKTARVY does not cure HIV-1 or AIDS. HIV-1 is the virus that causes AIDS.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about BIKTARVY®?
BIKTARVY may cause serious side effects:
- Worsening of hepatitis B (HBV) infection. Your healthcare provider will test you for HBV. If you have both HIV-1 and HBV and stop taking BIKTARVY, your HBV may suddenly get worse. Do not stop taking BIKTARVY without first talking to your healthcare provider, as they will need to monitor your health, and may give you HBV medicine.
Who should not take BIKTARVY?
Do not take BIKTARVY if you take:
- dofetilide
- rifampin
- any other medicines to treat HIV-1
What are the other possible side effects of BIKTARVY?
Serious side effects of BIKTARVY may also include:
- Changes in your immune system. Your immune system may get stronger and begin to fight infections that may have been hidden in your body. Tell your healthcare provider if you have any new symptoms after you start taking BIKTARVY.
- Kidney problems, including kidney failure. Your healthcare provider should do blood and urine tests to check your kidneys. If you develop new or worse kidney problems, they may tell you to stop taking BIKTARVY.
- Too much lactic acid in your blood (lactic acidosis), which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.
- Severe liver problems, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.
The most common side effects of BIKTARVY in clinical studies were diarrhea (6%), nausea (6%), and headache (5%). Tell your healthcare provider if you have any side effects that bother you or don’t go away.
What should I tell my healthcare provider before taking BIKTARVY?
- All your health problems. Be sure to tell your healthcare provider if you have or have had any kidney or liver problems, including hepatitis virus infection.
- All the medicines you take, including prescription and over-the-counter medicines, antacids, laxatives, vitamins, and herbal supplements. BIKTARVY and other medicines may affect each other. Keep a list of all your medicines and show it to your healthcare provider and pharmacist, and ask if it is safe to take BIKTARVY with all of your other medicines.
- If you are pregnant or plan to become pregnant. Tell your healthcare provider if you become pregnant while taking BIKTARVY.
- If you are breastfeeding (nursing) or plan to breastfeed. Talk to your healthcare provider about the risks of breastfeeding during treatment with BIKTARVY.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Important Facts about BIKTARVY, including important warnings.
What is BIKTARVY®?
BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in adults and children who weigh at least 55 pounds. It can either be used in people who have never taken HIV-1 medicines before, or people who are replacing their current HIV-1 medicines and whose healthcare provider determines they meet certain requirements.
BIKTARVY does not cure HIV-1 or AIDS. HIV-1 is the virus that causes AIDS.
